GABA: Function, Mechanism of Action, and Scientific Overview

What is GABA?

GABA stands for Gamma-Aminobutyric Acid. It is a non-proteinogenic amino acid, meaning it is not used by the body to synthesise proteins. Instead, it serves as a chemical messenger – a neurotransmitter.

As the most important inhibitory neurotransmitter of the central nervous system, GABA regulates neuroelectrical activity in the brain. Without sufficient GABA, electrical impulses in neurons could fire uncontrollably – a mechanism involved in epileptic seizures, among other conditions.

GABA influences numerous bodily functions including sleep regulation, muscle tone, pain perception and various cognitive processes. The precise role of exogenous GABA supplements in these functions remains an active area of research.

Occurrence in the Body

As an inhibitory neurotransmitter, GABA is most active in the brain and spinal cord. In mammals – including humans – an estimated 25 to 50 percent of all synapses contain GABA receptors, meaning a large proportion of synaptic connections can be modulated by GABA.[1]

Researchers have also shown that GABA is not confined to the brain but is present throughout the gastrointestinal tract – in both enteric nerves and endocrine cells. This suggests GABA may influence the digestive system as both a neurotransmitter and an endocrine mediator.[2]

GABA is synthesised in presynaptic neurons and stored in synaptic vesicles. The enzyme L-glutamic acid decarboxylase (GAD) – which requires vitamin B6 as a cofactor – determines the rate of GABA synthesis by converting the excitatory neurotransmitter glutamate into GABA.

Discovery History

GABA was first chemically synthesised in 1883. At that time it was known only as a metabolic product of plants and microorganisms. It was not until 1950 that researchers identified GABA in the mammalian brain. Its significance as an inhibitory neurotransmitter was not fully established until approximately 16 years later.

How Does GABA Work?

For neurons to transmit signals, they must communicate with one another. Because neurons are not directly connected, this communication occurs via neurotransmitters across a narrow gap called the synapse. The crossing of this gap is referred to as neurotransmission.

When an electrical signal (action potential) reaches the axon terminal, it triggers the release of small vesicles containing neurotransmitters. These diffuse across the synaptic cleft and bind to receptors on the neighbouring cell – following the lock-and-key principle. GABA binds exclusively to GABA receptors.

When GABA binds to its receptor, it causes hyperpolarisation of the postsynaptic neuron: the membrane's permeability to negatively charged chloride ions or positively charged potassium ions changes, lowering the membrane potential below the threshold needed for a new action potential – effectively halting signal transmission.

GABA and the Blood-Brain Barrier

The brain is protected by the blood-brain barrier – a specialised system of blood vessels that is semipermeable and strictly regulates which molecules can enter the brain.[3]

Whether orally ingested GABA can cross this barrier in humans has not been conclusively established. A review by a German and Dutch research group evaluated the findings of numerous studies on this question.[4]

Early animal studies from the 1950s suggested that GABA does not cross the blood-brain barrier. Later studies, however, indicated that limited permeability may be possible – potentially depending on the chemical form used or whether GABA was administered orally or by injection.

A 2001 study identified a GABA transporter in mice that could theoretically enable passage across the barrier. Whether a comparable transporter exists in humans has not yet been confirmed.[4]

Several placebo-controlled studies have observed positive effects following oral GABA intake. A possible explanation is an indirect effect via the enteric nervous system and the vagus nerve. The underlying mechanisms are still not fully understood and require further investigation.[3]

GABA Deficiency: What We Know

Reduced GABA levels in the brain have been associated in scientific studies with various neuropsychiatric conditions. The exact causes of GABA deficiency and the clinical relevance of these findings are subjects of ongoing research.

Possible factors that may contribute to lower GABA levels include chronic stress, nutritional deficiencies (particularly vitamin B6, which is a cofactor in GABA synthesis) and certain disorders of the nervous system.

GABA in Foods

GABA occurs naturally in a range of foods, particularly fermented products. The fermentation process can significantly increase the GABA content of foods, as certain lactic acid bacteria and yeasts can synthesise GABA from glutamate.

Note: Values are indicative based on available study data and may vary depending on the product, cultivation method and processing.

GABA and the Central Nervous System

The central nervous system (CNS) consists of the brain and spinal cord. GABA is the primary inhibitory neurotransmitter in this system, maintaining the balance between neuronal excitation and inhibition. This balance is essential for normal brain function.

GABA receptors in the CNS are divided into two main classes: GABA-A receptors (ionotropic – fast response via ion channels) and GABA-B receptors (metabotropic – slower response mediated via second messengers). Several medications, including benzodiazepines and barbiturates, exert their effects by modulating GABA-A receptor activity.

GABA as a Neurotransmitter

GABA belongs to the class of inhibitory neurotransmitters. Its primary function is to reduce neuronal excitability throughout the nervous system. The balance between excitatory glutamate and inhibitory GABA is critical for stable neural network function.

After release into the synaptic cleft, GABA is taken back up by specific transporter proteins (GAT-1, GAT-2, GAT-3) and can be recycled or broken down.

GABA and Glutamate

Glutamate and GABA are functional counterparts: glutamate is the primary excitatory neurotransmitter; GABA is the primary inhibitory one. The ratio of these two neurotransmitters regulates the overall excitability of neural networks.

Biochemically, they are closely linked: GABA is synthesised directly from glutamate by the enzyme glutamate decarboxylase (GAD), which requires pyridoxal phosphate (an active form of vitamin B6) as a cofactor.

GABA and Sleep: Research Findings

GABAergic neurons play a well-established role in sleep onset and maintenance. Certain sleep medications (e.g. benzodiazepines, zolpidem) work by enhancing GABA-A receptor activity.

Some smaller human studies have investigated exogenous GABA supplements and sleep. One study (Yamatsu et al., 2016) observed subjectively improved sleep onset latency in healthy adults taking 100 mg GABA daily. Study size and methodology do not yet allow definitive conclusions. Further well-designed studies are needed.

GABA and Stress Response: Research Findings

The GABAergic system is involved in modulating the stress axis (hypothalamic-pituitary-adrenal axis). Animal studies and some human studies have investigated whether increased GABA activity can dampen the physiological stress response.

A placebo-controlled study (Abdou et al., 2006) investigated the effects of orally administered GABA on stress-related parameters and observed changes in EEG readings and salivary markers. These findings are preliminary and require replication in larger studies. GABA supplements are not authorised as stress-reducing agents.

GABA and the Nervous System: What Research Shows

The GABAergic system is fundamentally involved in regulating states of neural excitability. Reduced GABAergic activity has been associated in imaging studies with certain conditions characterised by heightened neural excitability. The precise relationship between the GABA system and anxiety in humans is an active field of research.

Some human studies have investigated whether oral GABA intake can influence subjective relaxation-related parameters. Findings remain preliminary. Robust clinical evidence for the efficacy of GABA supplements in diagnosed anxiety disorders is currently lacking.

GABA and Immune Function

More recent research shows that GABA receptors are present on immune cells, suggesting a possible immunomodulatory role for GABA. Preclinical studies have investigated effects on T cells and macrophages. This research is still at an early stage; clinical data in humans are largely lacking.

GABA and Blood Sugar Regulation: Research Findings

GABA has been identified as a local signalling molecule in pancreatic islet cells (islets of Langerhans). Preclinical studies have investigated a possible role in regulating insulin secretion and beta-cell preservation. Clinically robust data on the effect of GABA supplements on blood sugar in humans are still lacking.

GABA and Mental Wellbeing: Current Evidence

Various studies have investigated a link between the central GABAergic system and mood regulation. Certain antidepressants and mood stabilisers indirectly modulate GABA activity. Whether direct GABA supplementation can influence subjective wellbeing is not yet sufficiently supported by clinical evidence.

GABA and PMS

Premenstrual syndrome (PMS) is associated with cyclical hormonal changes. Since progesterone metabolites (particularly allopregnanolone) act as positive allosteric modulators of GABA-A receptors, a link between GABAergic activity and PMS symptoms has been investigated. The evidence base is still limited and does not support a recommendation for GABA supplementation for PMS.

GABA and Growth Hormones

Some studies have investigated whether GABA can influence the release of growth hormone (GH) from the pituitary gland. One study (Powers et al., 2008) examined GABA in combination with exercise and observed elevated GH levels. The underlying mechanisms and clinical relevance of these findings have not been conclusively established.

GABA and Cognition

The GABAergic system is involved in various cognitive processes, including working memory, learning and attention regulation. Imaging studies show that GABA concentrations in certain brain regions correlate with cognitive performance. The relationship between exogenous GABA intake and cognitive function in humans is the subject of ongoing research.

GABA and Neural Activity: What We Know So Far

Basic research confirms that the GABAergic system plays a key role in modulating neural excitability. Some studies have described changes in GABAergic function in various neurological and psychiatric conditions. Clinical trials examining the targeted use of GABA supplements in humans in this context remain limited.

GABA as a Pharmaceutical Reference Point

GABA itself is not authorised as a medicinal product in the EU. However, certain pharmaceutical agents that modulate the GABAergic system are authorised medications, including:

• Benzodiazepines (e.g. diazepam) – positive modulators of GABA-A receptors
• Barbiturates – positive modulators of GABA-A receptors
• Gabapentin and pregabalin – structural analogues of GABA (acting via different mechanisms)
• Baclofen – a GABA-B receptor agonist, authorised for spasticity

These are prescription-only medicines that work differently from oral GABA food supplements and should only be taken on medical instruction.

GABA Food Supplements

GABA supplements are available as capsules, tablets or powders. Common forms include:

• Synthetic GABA: Chemically manufactured gamma-aminobutyric acid
• Natural GABA: GABA produced via microbial fermentation (often marketed as "natural GABA")
• PharmaGABA®: A specific fermentation-derived GABA form investigated in several studies

When purchasing, look for quality certifications, transparent ingredient lists and reputable manufacturers. Always follow the product information provided by the manufacturer.

Dosage Guidance

Figures are based on study data; individual variation may be significant. Consultation with a healthcare professional is strongly recommended.

Example Intake Schedule (General Orientation)

Note: The following schedule is provided for general orientation purposes only and is not an individual recommendation. Always discuss timing and dosage with a doctor or pharmacist before starting.

Interactions

Possible interactions have been noted with the following substance classes:

• Benzodiazepines & sleep medications: Possible additive CNS effect (enhanced sedation)
• Anticonvulsants: Possible influence on seizure threshold
• Antidepressants: Interactions cannot be excluded
• Antihypertensives: GABA may have blood-pressure-lowering properties at higher doses
• Alcohol: Combination not recommended (possible additive CNS effect)

Overdose

Robust data on GABA toxicity in humans at overdose levels are limited. Animal studies suggest relatively low acute toxicity. Taking significantly more than the recommended amount may result in intensified side effects (see below).

In case of accidental ingestion of large quantities, contact a poison control centre or doctor:

• Germany: 030 19240 (Berlin Poison Control Center) or 0228 19240 (Bonn)
• Austria: 01 406 43 43
• Switzerland: 145

Side Effects

GABA food supplements are generally well tolerated at recommended doses in clinical studies. Possible side effects, usually mild and transient, include:

• Tingling or numbness in hands or feet
• Mild drowsiness or dizziness
• Nausea or gastrointestinal discomfort
• Sensation of a racing heart (at higher doses)
• Shortness of breath at very high doses (rare)

References

1. Bloom, F. E., & Iversen, L. L. (1971). Localizing 3H-GABA in nerve terminals of rat cerebral cortex by electron microscopic autoradiography. Nature, 229(5287), 628–630. doi:10.1038/229628a0
2. Auteri, M., Zizzo, M. G., & Serio, R. (2015). GABA and GABA receptors in the gastrointestinal tract. Pharmacological Research, 93, 11–21. doi:10.1016/j.phrs.2014.12.001
3. Abdou, A. M. et al. (2006). Relaxation and immunity enhancement functions of gamma-aminobutyric acid (GABA) administration in humans. BioFactors, 26(3), 201–208. doi:10.1002/biof.5520260305
4. Boonstra, E. et al. (2015). Neurotransmitters as food supplements: the effects of GABA on brain and behaviour. Frontiers in Psychology, 6, 1520. doi:10.3389/fpsyg.2015.01520
5. Petroff, O. A. C. (2002). GABA and glutamate in the human brain. The Neuroscientist, 8(6), 562–573. doi:10.1177/1073858402238515
6. Yamatsu, A. et al. (2016). The improvement of sleep by oral intake of GABA and apocynum venetum leaf extract. Journal of Nutritional Science and Vitaminology, 62(3), 182–187. doi:10.3177/jnsv.62.182
7. Powers, M. E. et al. (2008). Growth hormone isoform responses to GABA ingestion at rest and after exercise. Medicine & Science in Sports & Exercise, 40(1), 104–110. doi:10.1249/mss.0b013e318158b518